Revive Therapeutics Ltd. (FRA:31R)

Germany flag Germany · Delayed Price · Currency is EUR
0.0005
0.00 (0.00%)
At close: Jan 30, 2026
Market Cap4.02M +188.0%
Revenue (ttm)n/a
Net Income-6.62M
EPS-0.02
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume9,024
Open0.0005
Previous Close0.0005
Day's Range0.0005 - 0.0005
52-Week Range0.0005 - 0.0235
Betan/a
RSI45.66
Earnings DateFeb 26, 2026

About Revive Therapeutics

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphe... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Michael Frank
Employees 2
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 31R
Full Company Profile

Financial Performance

Financial numbers in CAD Financial Statements